ATMI Invests in Sterile Fill and Connector Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ATMI Invests in Sterile Fill and Connector Technology



ATMI, a provider of single-use bioprocess solutions, has invested in sterile connector and sterile fill technology developed by Medical Instill Technologies (Medinstill), a provider of transfer and packaging solutions for high purity fluids at unmatched safety levels.

The investments focus on the INTACT family of products developed by Medinstill. These technologies will be deployed in sterile filling, sterile multiple-dose dispensing, sterile transfer, and packaging sterilization solutions.

In other news, ATMI has introduced a line of pyrogen-free vials in collaboration with Disposable Lab, a Bordeaux, France contract manufacturing organization

Source: ATMI

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here